Surgery Websites
Department of Surgery »  Faculty »  Adult Cardiothoracic Surgery »  David M. Jablons, M.D.
David M. Jablons, M.D., FACS

David M. Jablons, M.D., FACS

Professor and Chief, General Thoracic Surgery
Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology
Ada Distinguished Professor of Thoracic Oncology
Program Leader Thoracic Oncology
Director, Thoracic Oncology Laboratory,
UCSF Helen Diller Comprehensive Cancer Center

Contact Information

(415) 885-3882  Patients & Clinic
(415) 353-7151  Fax  
Open Popup
  • Yale University, B.A., American Literature, 1979
  • Albany Medical College of Union University, M.D., 1984
  • Oak Knoll Naval Hospital, Oakland, CA, General Surgery, 1984-85
  • Tufts University/New England Medical Center, General Surgery, 1985-86, 89-91
  • Weill Cornell University Medical Center, Cardiothoracic Surgery, 1991-93
  • NCI/NIH, Surgery Branch, Surgical Oncology, 1986-89
  • Brigham & Women's Hospital, Lung Transplantation, 1992
  • New York Hospital/Memorial Sloan Kettering Cancer Center, Thoracic Surgery, 1992-93
  • American Board of Surgery
  • American Board of Thoracic Surgery
  • Thoracic Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Inflammation in lung carcinogenesis
  • Study of "systems genetics" in thoracic malignancies
  • Isolation of lung cancer stems cells
  • Clinical outcomes research
  • Discovery of novel therapeutic targets in in thoracic malignancies
  • Early Detection and Screening
  • Investigation of signal transduction pathways including Wnt, Hedgehog, and Hippo in lung cancer and mesothelioma
  • Lung cancer epigenetics and emerging biomarkers
  • Next generation sequencing
  • Prognostic molecular multi-gene assays in Early-Stage NSCLC

David M. Jablons M.D., FACS is Professor and Chief of the Section of General Thoracic Surgery at UCSF, and Program Leader of Thoracic Oncology.  Dr. Jablons is also Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology. Dr. Jablons is Director of the Thoracic Oncology Lab, one of the largest in the Department of Surgery, with seven principal investigators, an enviable portfolio of NIH grants, and state-of-art-equipment. Utilizing next generation sequencing and leveraging one of the largest thoracic tissue banks in the world, the lab has compiled an enviable record of scientific discovery and invention including a life-saving prognostic assay that informs the decision for providing adjuvant therapy to early-stage lung cancer patients.

Dr. Jablons received his medical degree from Albany Medical College. During medical school, he was awarded an NCI preceptorship allowing him to train under Steven Rosenberg, a world-renowned surgeon and tumor immunologist. This experience kindled Dr. Jablons lifelong interest in translational and precision medicine. Dr. Jablons then completed his general surgery residency at Tufts-New England Medical Center and his thoracic surgery residency at what is now New York Presbyterian-Weill Cornell Medical Center. His mentors included Robert Ginsburg at Memorial Sloan-Kettering and David Sugarbaker at Brigham & Women's Hospital, both world-renown thoracic surgical oncologists. Dr. Jablons also served as a Navy commander while Chief of Thoracic Surgery at the Oakland Naval Hospital. In 1997, he was named Chief of General Thoracic Surgery at UCSF.

Dr. Jablons is a highly accomplished thoracic surgeon, widely sought out by patients in the Bay Area and world-wide. One patient, Bonnie J. Addario, after recovering from an arduous lung cancer surgery, started a foundation bearing her name she co-founded with Dr. Jablons. Today, the Addario Foundation is one of the leading underwriters of lung cancer research.  Dr. Jablons has also been a dedicated teacher and outstanding mentor for both for clinical fellows and surgical residents, the latter including Dan Raz and Johannes Kratz, protégés with an enviable and prolific record of publications who helped spearhead development of predictive and prognostic tools for lung cancer treatment in the lab.  

Dr. Jablons has been a trailblazer in educational outreach, co-founding the UCSF Thoracic Oncology Conference, an annual symposium that provided expert training for thousands of community surgeons for over a decade. He also was instrumental in establishing the China Clinical Trials Consortium to find more effective treatments for lung cancer, and to ameliorate the epidemic of lung cancer in China. In 2009, he led the effort to bring World Conference on Lung Cancer to San Francisco, the preeminent event in the field, in which he served as co-Chair. 

He is a member of numerous professional organizations including the Society of Thoracic Surgeons, the American College of Chest Physicians, the American Association for Cancer Research and the International Association for the Study of Lung Cancer (IASLC). Highly respected by his peers, Dr. Jablons was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty. Dr. Jablons was recently inducted into the American Surgical Society, the nation's most prestigious. 

  Confired By    
  • Surgical Resident Teaching Award
  • University of California, San Francisco
  • 2001
  • Surgical Resident Teaching Award
  • University of California, San Francisco
  • 1999
  • The Thoracic Oncology Lab focuses on drug target discovery, commercialization of novel therapeutics and development of genomic assays based on predictive and prognostic biomarkers.

    Data provided by UCSF Profiles, powered by CTSI
    • Inflammation and Lung Carcinogenesis
      Sponsor ID:
      Funding Period:
      May 2008
      Mar 2014
      Principal Investigator
    • The Wnt Pathway in Malignant Mesothelioma
      Sponsor ID:
      Funding Period:
      Mar 2005
      Feb 2010
      Principal Investigator
    Data provided by UCSF Profiles, powered by CTSI
    1. Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncol. 2021 Aug 26. View in PubMed
    2. Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021 Aug 20. View in PubMed
    3. Hysenaj L, Little S, Kulhanek K, Gbenedio OM, Rodriguez L, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Bahl K, Mick E, Li JZ, Ding VW, Matsumoto S, Maishan M, Simoneau C, Fragiadakis G, Jablons DM, Langelier CR, Matthay M, Ott M, Krummel M, Combes AJ, Sil A, Erle DJ, Kratz JR, Roose JP. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv. 2021 Jun 02. View in PubMed
    4. Yang YW, Jablons DM, Lemjabbar-Alaoui H. Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer. Exp Lung Res. 2021 May-Aug; 47(6):261-279. View in PubMed
    5. Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Ann Surg Oncol. 2021 Sep; 28(9):4953-4959. View in PubMed
    6. View All Publications
    • Mark Carpenter

      Preparing for a Triathlon after Outrunning Espophageal Cancer

      Mark Carpenter After Running NYC Marathon
      My name is Mark Carpenter, and I owe my life to the doctors and nurses at UCSF.  My story began in January 2010, when it became difficult to swallow. A few weeks later my general practitioner delivered the news that changed my life forever: I had esophageal cancer.  I went first to a surgeon in my local community who was unwilling to operate given the advanced stage of the tumor. Along with my wife, I decided to search for a second opinion. We were referred to UCSF where we met with Dr. David Jablons, chief of Thoracic Surgery and program leader of the Thoracic Oncology Program, who[...]
      Story Categories: Esophageal CancerEsophagectomy
    • Fran Cruse

      Surgery Gives Grandmother "A Cherished Gift Every Day"

      Fran Cruse With Her Grandchildren
      In 2002, my mother, Fran Cruse, was diagnosed with Stage II lung cancer. In the following months, my three siblings and I took her to surgeons and oncologists near her home in Carson City, Nevada. Because the tumor was extremely large and pressing against her aorta, the doctors told us there was nothing they could do – that she should just enjoy the time she had left with her family.  We were devastated. At the time, my mother was a vigorous 60-year-old woman with eight grandchildren. Although she had a serious illness, she wanted to do all she could to fight the cancer. We scoured the[...]
      Story Categories: Non-Small Cell Lung Cancer


    Site Directory